Member Info for ciaskin

PRESENTER: Bubacarr G Kaira

Unlocking the unique potential of AvidiMAb® in fighting cancer

Bubacarr G Kaira1, Foram Dave1, Elena Dubinina1, Omar Mohammed1, Ruhul Choudhury1, Tina Parsons1, and Mireille Vankemmelbeke1, and Lindy G. Durrant1,2

1 Scancell Ltd, University of Nottingham, Biodiscovery Institute, University Park, Nottingham NG7 2RD, United Kingdom
2 University of Nottingham, Biodiscovery Institute, Division of Cancer and Stem Cells, University Park, Nottingham NG7 2RD, United Kingdom

Avidity, the combined binding strength of individual interactions, is a key aspect of cancer-targeting by therapeutic antibodies.Strategies to enhance antibody avidity prove valuable in the context of prolonged target occupancy and/or enhanced signalling, two critical pharmacodynamic factors..
Using scancell’s proprietary method we have generated a series of anti-glycan monoclonal antibodies (GlyMab®) with
cancer therapy potential. These GlyMabs were subsequently avidity-enhanced leading to enhanced anti-tumour activity in vivo, through our Fc-engineering AvidiMab® technology (1) . Briefly, the introduction of select residues from murine IgG3, an isotype known to exhibit cooperative binding, promoted non-covalent Fc:Fc associations by neighbouring target-bound mAbs. We next sought to expand the applicability of our avidity-promoting strategy by focusing on agonistic mAbs with cancer immunotherapy potential such anti-CD40 agonists (2). CD40, a tumor necrosis factor receptor (TNFR) superfamily member, plays a critical role in B and T cell immunobiology. Agonistic CD40 mAbs act via mimicking CD40L-induced CD40 clustering and signalling thereby activating antigen presenting cells (APC) and expanding cytotoxic T cells(3). The CD40 interaction of parental SEA-CD40 and avidity-enhanced SEA-CD40 (iSEA-CD40), was analysed using SPR and higher order complex formation via DLS. Cell-based proliferation and activation assays were used to validate the observations. iSEA-CD40 displayed more avid CD40 binding and larger CD40 complex formation, in addition to exhibiting B cell superior proliferative capability, compared to SEA-CD40.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “Our proprietary antibody platforms leverage our skills and knowledge in immunology and we are excited about the future potential they give in creating truly differentiated product candidates for the treatment of certain types of cancer. The preclinical data being presented at EuroMAbNet illustrates the versatility and specificity of our platforms in generating novel antibody drug candidates using our GlyMab® technology and enhancing their anti-cancer potential with AvidiMab®.”

The four humanised monoclonal antibodies (mAbs) targeting glycans on lipids and/or proteins include candidates SC129, SC88, SC134 and SC27. The research shows that the Company’s GlyMab® candidates are highly specific for targets found in a broad range of cancers, making them viable candidates for cancer therapeutics.

Thanks for the insight, Berm - as ever!

If Keytruda is performing well in the neoadjuvant setting, wouldn't a combo protocol change to the adjuvant setting (i.e. where Keytruda is less effective) make more sense? At least initially, that is...

...to Dr Gillies O'Bryan Tear? Appointed as CMO in Nov 20 (RNS), media face of Scancell on Sky in 2021 and now not listed on company website. Equally, his LinkedIn profile does not even mention Scancell... Is he still there?

Ahem...just mixed up, I think Scouse!! I've been a holder here since 2010 and only ever added to my holding.
Long day - Night all.
C

Delayed trades from late morning...245,739 then 200,000 more within a minute. Then another 250,000 at 14p.
Something's bubbling...

Dare I say 'ARM Holdings'...???

From the PDF:

"During the majority of the financial year, Scancell’s share price fluctuated within a band of between 20p and 24p. From mid-January 2022, the Scancell share price entered a period of steady decline before recovering to 16.75p at 19 April following the announcement of the start of Modi-1 trials.
While it could be argued that Scancell has had a quiet year in terms of news flow and corporate milestones, the substantial injections of equity funding during 2020 have allowed Scancell to invest heavily in its technology platforms. Founder Professor Lindy Durrant is now back at the helm as CEO and Chief Scientific Officer, and Dr Richard Goodfellow is back as Interim Chief Business Officer. There have been subtle changes in the way Scancell positions itself in the market, the company now describing itself as a “clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease.
The company is building a pipeline of innovative products by utilising its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies”.
I remain positive about Scancell’s potential for treating otherwise untreatable diseases. Arguably the most important announcement made by Scancell during the course of the last 12 months was the news that the redemption date of the c. £19.7m of convertible loan notes held by Scancell’s major funder, US-based Redmile Group, LLC, were extended by three years (from 2022 to 2025), reducing the risk of an unfavourable dilutive event in 2022 and giving Scancell’s management the time to create maximum commercial value from its multiple ‘shots on goal’.
Post period end Scancell has received approval from the South Africa authorities to extend the scope of its Covidity trial.
As at the period end, Scancell made up 21% of OT3’s NAV, making it the Company’s second largest portfolio holding.

I think the other thing that may have prompted the most recent, and short-lived, surge in SAR was GSK's acquisition of Sierra to whom SAR have out-licensed one of their compounds. Lots of excitable conclusions being made over there, but it does not automatically follow that GSK will now buy out SAR.

Permission to shout BRAVO!
https://youtu.be/4vpfl9w6mbs

Your 8.23 is a top post, Burble! Many thanks.

Protocol expanded. As it should be !

Brexit notwithstanding, 'European Pharma' would also include the likes of GSK and AZ. Of the two, AZ would be the more likely.

Just the five and a half hours since I first alerted LSE, but at least it is there now!!

I have emailed admin twice and also contacted FTI (the IR firm behind the RNS) but still no action. LSE say that they have no direct control on what RNSs appear on their site (WHAT??) but that they have been in touch with their 'data supplier' and need to wait for them to send the information over to LSE in order for the RNS (and accompanying red dot) to appear.

Shocking

I've just emailed LSE about red dot...

Why no red dot on LSE? Anyone know how to contact Admin...?

Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™

Initial anti-glycan mAbs from the GlyMab™ platform have now been successfully humanised

Fourth research agreement on Glymab™ platform signed with major European Pharma.

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal antibody (mAb) platform, now branded GlyMab™. The Company’s fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats including antibody drug conjugate and CAR-T candidates. Scancell is developing a unique pipeline of tumour-specific anti-glycan antibodies with the initial aim of generating early-stage clinical data, either alone or in combination with potential strategic partners.

The Company currently has a pipeline of five anti-glycan mAbs: SC129, SC134, SC88 and SC27 that target solid tumours including pancreatic, small cell lung, colorectal and gastric, and SC2811 that targets a glycolipid on T cell stem cells. Four (SC129, SC27, SC134 and SC88) out of five of these drug candidates have now been successfully humanised and are therefore ready for the next stage of development.

In addition, the company is pleased to announce its fourth research collaboration agreement based on the Glymab™ platform. The agreement is with a major European pharmaceutical company and is designed to further evaluate one of the company’s Glymab™ antibodies for the treatment of cancer.